About Heqet Therapeutics
Heqet Therapeutics is a company based in Torino (Italy) founded in 2021. Heqet Therapeutics has raised $8.81 million across 1 funding round from investors including Claris Ventures and 2Invest AG. Heqet Therapeutics offers products and services including RNA-based Compounds. Heqet Therapeutics operates in a competitive market with competitors including Fagron, Ignota Labs, RareStone Group, Syntis and Revelation Pharma, among others.
- Headquarter Torino, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.81 M (USD)
in 1 rounds
-
Latest Funding Round
$8.81 M (USD), Series A
Mar 23, 2022
-
Investors
Claris Ventures
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Heqet Therapeutics
Heqet Therapeutics offers a comprehensive portfolio of products and services, including RNA-based Compounds.
Compounds targeting pathways for cardiovascular disease treatment
Funding Insights of Heqet Therapeutics
Heqet Therapeutics has successfully raised a total of $8.81M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.81 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Heqet Therapeutics
Heqet Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Claris Ventures and 2Invest AG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Claris Ventures is engaged in early-stage biotech venture investments.
|
Locked | Locked | Locked | |
|
Investments in biotechnology, life sciences, and IT are managed by 2Invest AG.
|
Locked | Locked | Locked |
Investor details for Heqet Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Heqet Therapeutics
Investment portfolio details for Heqet Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Heqet Therapeutics
Detailed financials for Heqet Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Heqet Therapeutics Comparisons
Peer comparison for Heqet Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Heqet Therapeutics
Heqet Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fagron, Ignota Labs, RareStone Group, Syntis and Revelation Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug compounding services are provided by Fagron.
|
|
| Locked | Locked | Locked |
AI-driven toxicity prediction tools for early-stage drug discovery scientists
|
|
| Locked | Locked | Locked |
Provider of network and treatments to individuals and their families affected by rare diseases drugs
|
|
| Locked | Locked | Locked |
Drug compounding services are provided by Syntis in healthcare.
|
|
| Locked | Locked | Locked |
A network of compounding pharmacies is operated nationwide.
|
|
| Locked | Locked | Locked |
Drug compounding services are provided to healthcare facilities nationwide.
|
Detailed competitors of Heqet Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Heqet Therapeutics
Complete news archive for Heqet Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Heqet Therapeutics
Heqet Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Heqet Therapeutics is headquartered in Torino, Italy. It is registered at Torino, Piemonte, Italy.
Marta Antonucci is the current CEO of Heqet Therapeutics.
Heqet Therapeutics is a funded company, having raised a total of $8.81M across 1 funding round to date.
Heqet Therapeutics was established in 2021 in Torino, Italy, within the biotechnology sector. Genetic medicines are focused on by the company for therapeutic applications. Operations are based in Italy, with services centered on research and development of targeted genetic treatments. Leadership is held by CEO Marta Antonucci, overseeing activities in this specialized field.
Heqet Therapeutics's top competitors include Syntis, Ignota Labs and Fagron.
Heqet Therapeutics offers RNA-based Compounds.
Heqet Therapeutics has 2 investors. Key investors include Claris Ventures, and 2Invest AG.